再鼎医药(ZLAB)今日盘中大涨5.88%,引发市场关注。
消息面上,高盛发表研究报告看好再鼎医药2025年的发展前景。报告指出,再鼎医药2024年第四季度收入同比增长66%,符合预期,各产品销售情况良好。高盛预计,2025年将是再鼎医药的重要里程碑年,预计下半年实现整体盈利。
高盛重点关注再鼎医药多款在研新药的进展,包括bemarituzumab在卵巢癌领域的新适应症申请、TIVDAK用于治疗三阴性乳腺癌的上市申请进展,以及肿瘤电场治疗仪Optune的新适应症申请等。高盛由于看好公司未来发展前景,给予再鼎医药"买入"评级,并上调股价目标价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.